- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
KraneShares MSCI All China Health Care Index ETF(KURE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for KURE
11/20/2026: KURE (1-star) is currently NOT-A-BUY. Pass it for now.
The KraneShares MSCI All China Health Care Index ETF (KURE) provides targeted exposure to China's expanding medical sector by tracking a market-cap-weighted index of companies listed across Mainland China, Hong Kong, and the US. Its primary strengths lie in its comprehensive share-class access and risk-mitigating 10/40 index capping methodology. It serves as a specialized satellite allocation for investors seeking growth in emerging market healthcare. Key risks involve high sector volatility, localized regulatory policy shifts, and geopolitical tensions. KURE best suits growth-focused investors with a high risk tolerance who wish to monitor demographic and medical reform catalysts in China.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Provides direct exposure to high-growth biotechnology and pharmaceutical innovators scaling rapidly within a major emerging market. |
| Momentum investor | Strong fit while signal remains positive | Captures sharp rotational momentum swings when Chinese equity markets experience positive sentiment rallies. |
| Value investor | Mixed fit | Valuations can be volatile and are frequently driven by growth expectations rather than traditional deep-value metrics. |
| Dividend/Income investor | Weak fit | The portfolio focuses primarily on capital appreciation and reinvestment in research-heavy medical firms rather than high dividend payouts. |
| Low-risk investor | Weak fit | Subject to substantial emerging market risks, regulatory shifts, and high sector-specific volatility. |
Investor Profile
Ideal Investor Profile
Growth-oriented investors looking for tactical, long-term exposure to the structural healthcare transformation and medical modernization taking place in China.
Suitability
Best suited for tactical long-term allocators willing to tolerate higher volatility in exchange for specialized emerging market sector growth.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The fund experiences sharp price fluctuations driven by sentiment shifts toward Chinese equities and the biotech sector. |
| Market risk | High | Performance is closely tied to macroeconomic and geopolitical developments affecting Greater China markets. |
| Concentration | Medium / high | Though capped, the portfolio concentrates heavily on a select group of top holdings and a single industry sector. |
| Tracking/expense | Low | The fund exhibits minimal tracking error relative to its benchmark index. |
| Liquidity | Medium | Underlying A-shares and niche listings can occasionally present localized liquidity constraints during market stress. |
| Business/sector quality | Medium / high | Constituents are subject to shifting clinical trial outcomes, regulatory approvals, and healthcare policy reforms. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
KURE displays high historical volatility relative to developed market healthcare funds due to emerging market exposure and single-sector concentration.
Market Risk
Subject to regulatory changes in China, currency fluctuations between the USD and RMB, and shifts in global investor sentiment toward Chinese assets.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Single stock | BeOne Medicines Ltd (06160) | 9.8 | Provides top-tier exposure to an innovative global-reaching biopharmaceutical entity shaping oncology therapeutics. |
| Single stock | Innovent Biologics Inc (01801) | 8.2 | Offers direct exposure to a premier Chinese biopharma leader specializing in monoclonal antibodies and oncology drugs. |
| Single stock | WuXi Biologics Cayman Inc (02269) | 7.6 | Captures growth in global life sciences contract research and biologics drug development manufacturing outsourcing. |
| Single stock | WuXi AppTec Co Ltd (603259) | 5.6 | Involves investors in a critical provider of R&D and manufacturing services for the worldwide pharmaceutical industry. |
| Sector | Remaining Chinese Healthcare Equities Basket | 68.8 | Diversifies the remainder of the fund across dozens of mid-to-large-cap pharmaceutical, medical device, and healthcare service providers. |
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit -8.05% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

